<DOC>
	<DOCNO>NCT01210482</DOCNO>
	<brief_summary>The objective investigation determine follow item patient receive Torisel certain period marketing : 1 . Confirmation efficacy safety medical practice use . 2 . Investigation factor may influence incidence adverse event ( Particularly priority investigation item ) . 3 . Investigation incidence status risk factor interstitial lung disease .</brief_summary>
	<brief_title>Temsirolimus ( Torisel ) Drug Use Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>Implemented Drug Use Investigation Central Registration System</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients treat Torisel ( patient metastatic and/or radically unresectable advanced renal cell carcinoma ) . Patients administered Torisel . Patients history severe hypersensitivity temsirolimus , sirolimus derivative , component and/or derivative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Torisel</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>